Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

NF2 Gene Mutation: early-phase trial registry

1 of 1 indexed NF2 Gene Mutation trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

NF2 Gene Mutation: 1 US clinical trial tracked, 1 recruiting.

NF2 Gene Mutation is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Alliance for Clinical Trials in Oncology, running 1 of these trials.

Enrollment posture brief

Registry condition nf2-gene-mutation

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

NF2 Gene Mutation (this)100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near NF2 Gene Mutation

NF2 Gene Mutation lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for NF2 Gene Mutation on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. NF2 Gene Mutation is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Named interventions

Most-linked intervention names on NF2 Gene Mutation records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

FAK Inhibitor GSK2256098 Drug
1 trials
Capivasertib Drug
1 trials
Vismodegib Drug
1 trials
Abemaciclib Drug
1 trials

US sites by state

Facility locations filed on NF2 Gene Mutation trials. A trial with sites in several states counts in each.

California 1 trials
Arizona 1 trials
Arkansas 1 trials
Alabama 1 trials
Alaska 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this NF2 Gene Mutation page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This NF2 Gene Mutation condition card totals 1 registered trials; most-linked intervention FAK Inhibitor GSK2256098; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.